Biogen licenses experimental drug with Alzheimer’s potential – The Boston Globe

April 13, 2017 by  
Filed under Alzheimers News

Sponsored By

Boston Business Journal
Biogen licenses experimental drug with Alzheimer's potential
The Boston Globe
As it moves to build a future franchise in Alzheimer's disease treatments, Biogen Inc. will pay $300 million upfront and up to $410 million more in potential milestone payments to license an experimental drug from pharmaceutical giant Bristol-Myers Squibb.
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drugBoston Business Journal
Bristol-Myers offloads anti-tau, DMD assets to Biogen, RocheFierceBiotech
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers SquibbBusiness Wire (press release)
BioPharma Dive
all 19 news articles »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!